Lineage Cell Therapeutics CEO Brian Culley purchased 15,000 shares at $1.62 on March 12, 2026, marking the largest purchase of his career and a reversal after eight consecutive sales. This insider buying comes as the stock trades near its 52-week low of $0.3651, potentially signaling confidence in the company's pipeline despite recent operational challenges.
Price context
The stock has dropped 14.13% over the past 30 days to trade at $1.58, sitting 24.4% below its 52-week high of $2.09 but still 332.76% above its low of $0.3651.
Catalysts to watch
- •The launch of the COR1 program on March 31, 2026, targeting corneal endothelial disease.
- •The upcoming Q1 2026 earnings call on May 15, 2026, where management highlighted progress in the OpRegen and COR1 programs.
- •The CEO's reversal after eight consecutive sales, signaling a potential shift in sentiment.
Risks
- •The stock faces significant short-term pressure with a short interest of 17.19% of the float.
- •The company reported a -50% earnings surprise and -46.53% revenue miss in Q1 2026, indicating operational challenges and lagging revenue estimates.
AI-generated context from public data. Not investment advice. Verify before trading.